ITC Determines Healthgen’s Medium Grade Products Did Not Infringe Ventria’s Patent

FOR IMMEDIATE RELEASE
September 16, 2022

WASHINGTON, DC—In a win for Finnegan client Wuhan Healthgen Biotechnology Corp., the U.S. International Trade Commission (ITC) reversed the ALJ’s finding of infringement by the powder products. Specifically, the ITC determined that Healthgen’s medium grade recombinant serum albumins (rHSA) did not infringe Ventria Bioscience’s 10,618,951 patent (the ‘951 patent). The ITC's corresponding opinion is sealed.

Contacts: 

Erika H. Arner, Managing Partner
erika.arner@finnegan.com

Anand K. Sharma, Chair
anand.sharma@finnegan.com

About Finnegan

Finnegan, Henderson, Farabow, Garrett & Dunner, LLP is one of the largest IP law firms in the world. From offices in Atlanta, Boston, London, Munich, Palo Alto, Reston, Seoul, Shanghai, Taipei, Tokyo, and Washington, DC, the firm practices all aspects of patent, trademark, and copyright law, including counseling, prosecution, licensing, and litigation. Finnegan also represents clients on IP issues related to advertising, trade secret law, European patents and trade marks, international trade, portfolio management, the Internet, e-commerce, government contracts, antitrust, and unfair competition. For additional information on the firm, please visit www.finnegan.com. Follow us on LinkedIn and Twitter.